அலார் மருந்துகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அலார் மருந்துகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அலார் மருந்துகள் Today - Breaking & Trending Today

Breaking the Cycle of Opioid Addiction: Alar Presents Positive [...] | Comunicati stampa CataniaOggi


10 marzo 2021 09:05
Fonte: Adnkronos
#chimica-e-farmacia
TAICHUNG, March 10, 2021 /PRNewswire/ Alar Pharmaceuticals Inc. (TWSE:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs) for central nervous system disorders, announces positive interim results from the single-ascending-dose study of ALA-1000. A 3-month buprenorphine released injectable designed to be dosed subcutaneously for treating opioid use disorder (OUD).
The Buprenorphine release from the ALA-1000 single injection lasts over 12 weeks with effective concentrations, showing low initial burst without dose dumping effect and good safety and tolerability, including local skin irritation and injection pain severity.
Opioid dependency: A world health issue
The world-wide opioid epidemic is a documented public health crisis. Treatments for opioid abuse currently rely on Buprenorphine, Methadone, and Naltrexone as Medication-assisted treatment (MAT). ....

Charles Lin , Prnewswire Alar Pharmaceuticals Inc , Dalar Pharmaceuticals , Alar Pharmaceuticals Inc , Shun Wen , Alar Pharmaceuticals Established , சார்லஸ் லின் , அலார் மருந்துகள் , அலார் மருந்துகள் இன்க் , விலக்கு வென் , அலார் மருந்துகள் நிறுவப்பட்டது ,